Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2024Open Access

Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMichael BeckPromega (United States)VBViktoria BlumenbergHarvard UniversityVBVeit BückleinLMU Klinikum

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Beck et al. (2024) studied this question.

synapsesocial.com/papers/68e67e23b6db643587607de3https://doi.org/10.21203/rs.3.rs-4401452/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predicting survival outcomes in CAR-t treated B-cell lymphoma by combining PET/CT imagingand clinical features2025
  2. 2Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy2025
  3. 3FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)2024
  4. 4[18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis2025
  5. 5Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma2026